Peer Reviewed

Antibody-Drug Conjugates in Oncology: Why Potency Is No Longer the Limiting Factor

How CDMOs Can Unlock One-step, High-Yield and Homogeneous ADC Manufacturing

Acute Myeloid Leukemia (AML) is a heterogeneous and highly aggressive hematologic malignancy characterized by a wide range of cytogenetic and molecular abnormalities that define distinct disease subgroups.

Reviewing the Key Trends and Insights from the ADC Linker & Conjugation Summit

3rd Antibody-Drug Conjugate (ADC)  in Boston, MA, brought together a group of diverse yet deeply specialized experts who shared their knowledge, clinical insights, and technical experience with remarkable openness and clarity.

The Opportunity to go Beyond “chemo on a stick” ADCs

Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceuticals that combine the selectivity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. This targeted delivery system has redefined oncology treatment by reducing systemic toxicity and improving efficacy. ADCs are composed of a tumor-targeting antibody, a cytotoxic agent, and a chemical linker, which together create a complex structure that presents various analytical challenges.

Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is projected to reach $11.29 billion in 2023, with an estimated compound annual growth rate (CAGR) of 9.2% between 2024 and 2030, reflecting substantial economic and scientific interest in this field

Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload...

Antibody-drug conjugates (ADCs) is a growing field requiring specific handling due to the highly potent drug or highly active pharmaceutical ingredient (HAPI). The generic...